Knight Therapeutics (TSE:GUD) issued its quarterly earnings data on Thursday. The company reported C$0.03 earnings per share (EPS) for the quarter, hitting the consensus estimate of C$0.03, Morningstar.com reports. The firm had revenue of C$3.22 million for the quarter, compared to analyst estimates of C$2.26 million.
Shares of GUD stock opened at C$8.30 on Friday. Knight Therapeutics has a 1 year low of C$7.38 and a 1 year high of C$8.81.
Several equities analysts recently issued reports on GUD shares. TD Securities lifted their price objective on Knight Therapeutics from C$9.50 to C$10.00 in a report on Friday, August 10th. Bloom Burton reaffirmed an “accumulate” rating on shares of Knight Therapeutics in a report on Friday. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of C$10.15.
About Knight Therapeutics
Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.
Read More: What is the Book Value of a Share?
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.